Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | STK17B | O94768 | 1/20 | 0.40 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13510973 | 0.94 | TDP1 (0.41) | TDP1CSNK1DMAOAMAOBBCHE | |
| SCHEMBL15494280 | 0.93 | CA12 (0.44) | TDP1CSNK1DMAOAMAOBBCHE | |
| SCHEMBL12185448 | 0.89 | TDP1 (0.46) | TDP1MAOAMAOBCA12CA1 | |
| SCHEMBL1134533 | 0.83 | TDP1 (0.49) | TDP1MAOAMAOBCA12CA1 | |
| SCHEMBL2838329 | 0.80 | BCHE (0.48) | TDP1BCHEMEN1GAAKMT2A | |
| SCHEMBL18337899 | 0.77 | HTT (0.42) | TDP1CSNK1DMAOAMAOBBCHE | |
| SCHEMBL3341020 | 0.77 | TDP1 (0.67) | TDP1MAOAMAOBBCHECA12 | |
| SCHEMBL17299222 | 0.77 | MLYCD (0.47) | L3MBTL1ALDH1A1 | |
| SCHEMBL2846431 | 0.77 | STK17B (0.45) | TDP1BCHEMEN1GAAKMT2A | |
| SCHEMBL15185777 | 0.74 | KDM4E (0.43) | TDP1GAAKMT2AL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12303570-B2 | Compositions and methods for assessing eye vasculature | MEDIBEACON INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20230173111-A1 | COMPOSITIONS AND SYSTEMS FOR RENAL FUNCTION DETERMINATION | MEDIBEACON INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230173111-A1 | COMPOSITIONS AND SYSTEMS FOR RENAL FUNCTION DETERMINATION | MEDIBEACON INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230158175-A1 | METHODS FOR RENAL FUNCTION DETERMINATION | MEDIBEACON INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158175-A1 | METHODS FOR RENAL FUNCTION DETERMINATION | MEDIBEACON INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230132384-A9 | COMPOSITIONS AND METHODS FOR ASSESSING EYE VASCULATURE | MEDIBEACON INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230132384-A9 | COMPOSITIONS AND METHODS FOR ASSESSING EYE VASCULATURE | MEDIBEACON INC. | 2023-04-27 | — | — | US | disclosed |
| US-11602570-B2 | Compositions and systems for renal function determination | MEDIBEACON INC. (US) | 2023-03-14 | — | — | US | disclosed |
| US-11590244-B2 | Methods for renal function determination | MEDIBEACON INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20220016269-A1 | COMPOSITIONS AND METHODS FOR ASSESSING EYE VASCULATURE | MEDIBEACON INC (US) | 2022-01-20 | — | — | US | disclosed |
| EP-2145879-A1 | Pyrazine derivatives, methods of use, and methods for preparing same | Mallinckrodt Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20100010223-A1 | Pyrazine derivatives, Methods of use, and methods for preparing same | MALLINCKRODT INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100010223-A1 | Pyrazine derivatives, Methods of use, and methods for preparing same | MALLINCKRODT INC. (US) | 2010-01-14 | — | — | US | disclosed |
| EP-2143716-A1 | Pyrazine derivatives, methods of use, and methods for preparing same | Mallinckrodt Inc. (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20090198053-A1 | Pyrazine Derivatives and Uses Thereof in Renal Monitoring | MEDIBEACON INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090198053-A1 | Pyrazine Derivatives and Uses Thereof in Renal Monitoring | MEDIBEACON INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090198053-A1 | Pyrazine Derivatives and Uses Thereof in Renal Monitoring | MEDIBEACON INC. | 2009-08-06 | — | — | US | disclosed |
| WO-2009061473-A2 | PHOTONIC SHELL-CORE CROSS LINKED AND FUNCTIONALIZED NANOSTRUCTURES FOR BIOLOGICAL APPLICATIONS | MALLINCKRODT INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009061473-A2 | PHOTONIC SHELL-CORE CROSS LINKED AND FUNCTIONALIZED NANOSTRUCTURES FOR BIOLOGICAL APPLICATIONS | MALLINCKRODT INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| WO-2007149479-A1 | PYRAZINE DERIVATIVES AND USES THEREOF IN RENAL MONITORING | MALLINCKRODT INC. (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11602570-B2 | Compositions and systems for renal function determination | GLS, ATP6V1B1, REN | TDP1 2576/4885CSNK1D 4611/4885MAOA 3447/4885 |
| US-20100010223-A1 | Pyrazine derivatives, Methods of use, and methods for preparing same | DPYD, DHPS, DHX15 | TDP1 747/4885CSNK1D 4265/4885MAOA 303/4885 |
| US-20230132384-A9 | COMPOSITIONS AND METHODS FOR ASSESSING EYE VASCULATURE | LIPG, FLT4, FABP3 | TDP1 1779/4885CSNK1D 3816/4885MAOA 1670/4885 |
| US-20230173111-A1 | COMPOSITIONS AND SYSTEMS FOR RENAL FUNCTION DETERMINATION | GLS, ATP6V1B1, REN | TDP1 2576/4885CSNK1D 4611/4885MAOA 3447/4885 |
| US-20090198053-A1 | Pyrazine Derivatives and Uses Thereof in Renal Monitoring | GLS, CYP3A5, PYCR1 | TDP1 3113/4885CSNK1D 2443/4885MAOA 676/4885 |
| US-11590244-B2 | Methods for renal function determination | GLS, REN, ATP6V1B1 | TDP1 2722/4885CSNK1D 4461/4885MAOA 1251/4885 |
| US-20230158175-A1 | METHODS FOR RENAL FUNCTION DETERMINATION | GLS, SHBG, OGFR | TDP1 3799/4885CSNK1D 3709/4885MAOA 2071/4885 |
| US-12303570-B2 | Compositions and methods for assessing eye vasculature | LIPG, FLT4, FABP3 | TDP1 1779/4885CSNK1D 3816/4885MAOA 1670/4885 |
| US-20220016269-A1 | COMPOSITIONS AND METHODS FOR ASSESSING EYE VASCULATURE | LIPG, FLT4, FABP3 | TDP1 1779/4885CSNK1D 3816/4885MAOA 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.